Notice of Special Interest (NOSI): Administrative Supplements to Existing R01 Grants on Polycystic Kidney Disease (PKD)
Notice Number:
NOT-DK-20-033

Key Dates

Release Date:

May 29, 2020

First Available Due Date:
July 15, 2020
Expiration Date:
July 16, 2020

Related Announcements

PA-18-591: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

Issued by

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Purpose

NIDDK is issuing this Notice of Special Interest (NOSI) to announce the opportunity for investigators with active NIDDK-supported R01 grants that focus on Polycystic Kidney Disease (PKD) to apply for administrative supplements. The intent of these supplements is to catalyze and accelerate the pace and achievement of scientific research related to PKD.

Background

There remain major gaps in our understanding of the pathways which lead to the development of polycystic kidney disease. Challenges to early diagnosis and prognosis also remain. These gaps and challenges have slowed the development of treatment strategies which would prevent or delay the development of chronic kidney failure, as well as the other complications of PKD. The NIDDK seeks to support a broad and dynamic portfolio of PKD research and has planned a supplement mechanism to accomplish this goal.

Research Objectives

The projects proposed in the Administrative Supplements must be within the scope of the currently active R01 award but should extend or expand upon the work proposed in the original application.

Important Consideration: What activities are considered within scope and what would be a change in scope ? See the NIH Grants Policy Statement, section on Change in Scope NIH external link, for more information.

Application and Submission Information

Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent.

  • PA-18-591 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

All instructions in the SF424 (R&R) Application Guide and PA-18-591 must be followed, with the following additions:

  • Application Due Date July 15th, 2020, by 5:00 PM local time of applicant organization.
  • For funding consideration, applicants must include NOT-DK-20-033 (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.
  • Requests may be for one year of support only.
  • The budget is limited to $100,000 in direct costs.
  • The Research Strategy section of the application is limited to 6 pages.
  • Only existing awardees of NIDDK-supported R01 grants focused on PKD are eligible to apply.
  • Administrative supplement applications to PA-18-591 must use the application form package with the Competition ID that contains FORMS-F-ADMINSUPP . The process for Streamlined Submissions using the eRA Commons cannot be used for this initiative.
  • Applicants are strongly encouraged to notify the program contact at the Institute supporting the parent award that a request has been submitted in response to this FOA in order to facilitate efficient processing of the request.

Inquiries

Please direct all inquiries to:

Susan Mendley, M.D.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301-827-1861
Email: susan.mendley@nih.gov


Christine Maric-Bilkan, Ph.D.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301-435-0486
Email: christine.maric-bilkan@nih.gov


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices